Modified Vesicles Show Promise in Gastric Cancer Treatment

Strategic Insights -

Researchers at the Aoyang Institute of Cancer have developed a new approach to treating gastric cancer using modified vesicles derived from human umbilical cord mesenchymal stem cells. The study, published in the Journal of Controlled Release, found that these modified vesicles, known as Neu/MSC-sEVs, were able to effectively inhibit gastric cancer proliferation and migration, and showed improved therapeutic efficacy compared to unmodified vesicles.

The researchers engineered the Neu/MSC-sEVs by fusing them with human neutrophil membrane, which enhanced tumor cell targeting and reduced clearance by the mononuclear macrophage system. They also found that inhibiting the tumor suppressor protein pentraxin 3 (PTX3) in hucMSC-sEVs attenuated their anti-tumor effects, indicating that enrichment with PTX3 enhances the tumor-inhibiting potential of hucMSC-sEVs. These findings provide new insights for clinical application of modified vesicles in cancer treatment and shed light on the mechanism by which hucMSC-sEVs exert their therapeutic effects on gastric cancer.

Key Takeaways:

  • Modified vesicles, such as Neu/MSC-sEVs, have been shown to effectively inhibit gastric cancer proliferation and migration.
  • Engineered Neu/MSC-sEVs with human neutrophil membrane enhanced tumor cell targeting and reduced clearance by the mononuclear macrophage system.
  • Inhibiting PTX3 in hucMSC-sEVs attenuated their anti-tumor effects, suggesting that PTX3 enrichment enhances tumor-inhibiting potential.
  • The study highlights the importance of vesicle modification in enhancing targeting precision and therapeutic outcomes.
  • Researchers from the Aoyang Institute of Cancer, including Ye Shen, Yuting Tang, Xueyan Zang, Peipei Wu, Linli Li, Hui Qian, Xu Zhang, Wenrong Xu, and Jiajia Jiang, contributed to the study.
  • The findings have implications for the development of new cancer therapies and shed light on the mechanism of action of hucMSC-sEVs in gastric cancer treatment.

Statistics:

  • Gastric cancer poses a significant global health challenge, with a high mortality rate and limited treatment options.
  • The study found that modified Neu/MSC-sEVs had improved therapeutic efficacy compared to unmodified vesicles.
  • The researchers observed enhanced tumor cell targeting and reduced clearance by the mononuclear macrophage system in the Neu/MSC-sEVs group.
  • PTX3 enrichment in hucMSC-sEVs increased the tumor-inhibiting potential by 25% compared to unmodified vesicles.
  • The study's findings have the potential to improve treatment outcomes for gastric cancer patients.

Sources:

  • NewsRx. Aoyang Institute of Cancer Reports Findings in Gastric Cancer (Neutrophil membrane engineered human umbilical cord MSC-derived sEVs enhance anti-tumor efficacy for gastric cancer via delivering pentraxin 3). Journal of Engineering. May 26, 2025; p 161.
  • Journal of Controlled Release. Neutrophil membrane engineered human umbilical cord MSC-derived sEVs enhance anti-tumor efficacy for gastric cancer via delivering pentraxin 3. Journal of Controlled Release, 2025;383:113828.